Announced
Synopsis
Jounce Therapeutics, a clinical-stage immunotherapy company, terminated the $425m merger with Redx Pharma, a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of cancer and fibrotic diseases and the emerging area of cancer-associated fibrosis. Jounce's decision was based upon the receipt of an unsolicited proposal from Concentra Biosciences, which led to Jounce entering into a merger agreement whereby Concentra will acquire Jounce through a cash tender offer
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.